Home > Research > Publications & Outputs > A case of insulin and ACTH co-secretion by a ne...

Links

Text available via DOI:

View graph of relations

A case of insulin and ACTH co-secretion by a neuroendocrine tumour

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

A case of insulin and ACTH co-secretion by a neuroendocrine tumour. / Solomou, S; Khan, R; Propper, D; Berney, D; Druce, M.

In: Endocrinology, diabetes & metabolism case reports, Vol. 2014, No. 1, 130082, 01.02.2014.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Solomou, S, Khan, R, Propper, D, Berney, D & Druce, M 2014, 'A case of insulin and ACTH co-secretion by a neuroendocrine tumour', Endocrinology, diabetes & metabolism case reports, vol. 2014, no. 1, 130082. https://doi.org/10.1530/EDM-13-0082

APA

Solomou, S., Khan, R., Propper, D., Berney, D., & Druce, M. (2014). A case of insulin and ACTH co-secretion by a neuroendocrine tumour. Endocrinology, diabetes & metabolism case reports, 2014(1), [130082]. https://doi.org/10.1530/EDM-13-0082

Vancouver

Solomou S, Khan R, Propper D, Berney D, Druce M. A case of insulin and ACTH co-secretion by a neuroendocrine tumour. Endocrinology, diabetes & metabolism case reports. 2014 Feb 1;2014(1). 130082. https://doi.org/10.1530/EDM-13-0082

Author

Solomou, S ; Khan, R ; Propper, D ; Berney, D ; Druce, M. / A case of insulin and ACTH co-secretion by a neuroendocrine tumour. In: Endocrinology, diabetes & metabolism case reports. 2014 ; Vol. 2014, No. 1.

Bibtex

@article{3fefa70d901643d380c53eac0e47c076,
title = "A case of insulin and ACTH co-secretion by a neuroendocrine tumour",
abstract = " A 33-year-old male was diagnosed with a metastatic neuroendocrine carcinoma of uncertain primary. He defaulted from follow-up without therapy and some months later developed episodic severe hypoglycaemia, which was found to be associated with inappropriately elevated insulin and C-peptide levels. It was considered likely that the neuroendocrine tumour was the source of the insulin secretion. Diazoxide and somatostatin analogue were used to control hypoglycaemia. Much later in the course of the disease, he developed metabolic derangement, increased skin pigmentation and psychological disturbance, without frankly Cushingoid physical findings. Investigations revealed highly elevated cortisol levels (the levels having previously been normal) with markedly raised ACTH levels, consistent with the co-secretion of ACTH and insulin by the tumour. Treatment with metyrapone improved his psychological state and electrolyte imbalance. Unfortunately, despite several cycles of first-, second- and third-line chemotherapy from the start of the first hormonal presentation onwards, imaging revealed widespread progressive metastatic disease and the patient eventually passed away. This case highlights the importance of keeping in mind the biochemical heterogeneity of endocrine tumours during their treatment.LEARNING POINTS: The clinical presentation of insulin-secreting tumours includes symptoms of neuroglycopaenia and sympathetic overstimulation.Tumour-associated hypoglycaemia can be due to pancreatic insulinomas, and although ectopic hormone production occurs in a number of tumours, ectopic secretion of insulin is rare.A possible switch in the type of hormone produced can occur during the growth and progression of neuroendocrine tumours and, when treating neuroendocrine tumours, it is important to keep in mind their biochemical heterogeneity.",
author = "S Solomou and R Khan and D Propper and D Berney and M Druce",
year = "2014",
month = feb,
day = "1",
doi = "10.1530/EDM-13-0082",
language = "English",
volume = "2014",
journal = "Endocrinology, diabetes & metabolism case reports",
issn = "2052-0573",
publisher = "BioScientifica Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - A case of insulin and ACTH co-secretion by a neuroendocrine tumour

AU - Solomou, S

AU - Khan, R

AU - Propper, D

AU - Berney, D

AU - Druce, M

PY - 2014/2/1

Y1 - 2014/2/1

N2 -  A 33-year-old male was diagnosed with a metastatic neuroendocrine carcinoma of uncertain primary. He defaulted from follow-up without therapy and some months later developed episodic severe hypoglycaemia, which was found to be associated with inappropriately elevated insulin and C-peptide levels. It was considered likely that the neuroendocrine tumour was the source of the insulin secretion. Diazoxide and somatostatin analogue were used to control hypoglycaemia. Much later in the course of the disease, he developed metabolic derangement, increased skin pigmentation and psychological disturbance, without frankly Cushingoid physical findings. Investigations revealed highly elevated cortisol levels (the levels having previously been normal) with markedly raised ACTH levels, consistent with the co-secretion of ACTH and insulin by the tumour. Treatment with metyrapone improved his psychological state and electrolyte imbalance. Unfortunately, despite several cycles of first-, second- and third-line chemotherapy from the start of the first hormonal presentation onwards, imaging revealed widespread progressive metastatic disease and the patient eventually passed away. This case highlights the importance of keeping in mind the biochemical heterogeneity of endocrine tumours during their treatment.LEARNING POINTS: The clinical presentation of insulin-secreting tumours includes symptoms of neuroglycopaenia and sympathetic overstimulation.Tumour-associated hypoglycaemia can be due to pancreatic insulinomas, and although ectopic hormone production occurs in a number of tumours, ectopic secretion of insulin is rare.A possible switch in the type of hormone produced can occur during the growth and progression of neuroendocrine tumours and, when treating neuroendocrine tumours, it is important to keep in mind their biochemical heterogeneity.

AB -  A 33-year-old male was diagnosed with a metastatic neuroendocrine carcinoma of uncertain primary. He defaulted from follow-up without therapy and some months later developed episodic severe hypoglycaemia, which was found to be associated with inappropriately elevated insulin and C-peptide levels. It was considered likely that the neuroendocrine tumour was the source of the insulin secretion. Diazoxide and somatostatin analogue were used to control hypoglycaemia. Much later in the course of the disease, he developed metabolic derangement, increased skin pigmentation and psychological disturbance, without frankly Cushingoid physical findings. Investigations revealed highly elevated cortisol levels (the levels having previously been normal) with markedly raised ACTH levels, consistent with the co-secretion of ACTH and insulin by the tumour. Treatment with metyrapone improved his psychological state and electrolyte imbalance. Unfortunately, despite several cycles of first-, second- and third-line chemotherapy from the start of the first hormonal presentation onwards, imaging revealed widespread progressive metastatic disease and the patient eventually passed away. This case highlights the importance of keeping in mind the biochemical heterogeneity of endocrine tumours during their treatment.LEARNING POINTS: The clinical presentation of insulin-secreting tumours includes symptoms of neuroglycopaenia and sympathetic overstimulation.Tumour-associated hypoglycaemia can be due to pancreatic insulinomas, and although ectopic hormone production occurs in a number of tumours, ectopic secretion of insulin is rare.A possible switch in the type of hormone produced can occur during the growth and progression of neuroendocrine tumours and, when treating neuroendocrine tumours, it is important to keep in mind their biochemical heterogeneity.

U2 - 10.1530/EDM-13-0082

DO - 10.1530/EDM-13-0082

M3 - Journal article

C2 - 24683485

VL - 2014

JO - Endocrinology, diabetes & metabolism case reports

JF - Endocrinology, diabetes & metabolism case reports

SN - 2052-0573

IS - 1

M1 - 130082

ER -